Description
Travaxal Pharmacodynamics
Travoprost, a synthetic analog of prostaglandin F2-alpha, is a highly selective full agonist of prostaglandin receptors FP and decreases intraocular pressure by increasing aqueous outflow through the trabecular meshwork and uveoscleral pathways.
Intraocular pressure decreases approximately 2 hours after application, and the maximum effect is achieved after 12 hours. Significant decrease in intraocular pressure may persist for 24 hours after a single application of the drug.
Indications
Reduction of increased intraocular pressure in:
– open-angle glaucoma;
– Increased intraocular pressure.
Contraindications
Hypersensitivity to the components of the drug, children under 18 years of age, pregnancy and breast-feeding.
Caution
The drug should be used with caution in patients with aphakia; in patients with pseudophakia in case of rupture of the posterior lens capsule or in patients with the anterior chamber intraocular lens; in patients with the risk of cystoid macular edema.
The drug should be used with caution in patients with acute inflammatory phenomena of the visual organ and in patients with risk factors predisposing to iritis, uveitis.
Usage during pregnancy and breast feeding period
Pregnancy
There are no or limited data on the use of hervoprost in pregnant women. Animal studies with hervoprost have shown reproductive toxicity.
Women during pregnancy, as well as women planning to become pregnant, should refrain from direct contact with substances containing prostaglandins. Prostaglandins and prostaglandin analogues are biologically active substances that can be absorbed through the skin.
Women during pregnancy, as well as women planning to become pregnant, should take appropriate precautions to avoid direct contact of the vial contents with the skin. If a significant portion of the contents of the vial does get on the skin (which is unlikely), the area of skin on which the drug has come into contact should be immediately rinsed with water.
Breast-feeding period
There are no data on whether travoprost and/or metabolites penetrate into breast milk.
Fertility
No studies have been done to evaluate the effects of hervoprost on human fertility. Animal studies have shown that there is no effect of hervoprost on fertility when used in doses greater than 250 times the maximum recommended dose for humans.
Directions for use and dosages
- Topically.
- One drop in the conjunctival sac of the eye (eye) once a day, in the evening. To reduce the risk of systemic side effects it is recommended after instillation to squeeze the nasolacrimal duct by pressing on its projection at the inner corner of the eye.
- If a dose of the drug was missed, treatment should be continued with the next dose. Daily dose of the drug shall not exceed 1 drop in the conjunctival sac of the eye once a day.
- The drug may be used in combination with other local ophthalmic drugs for reduction of intraocular pressure. In this case the interval between their application should be at least 5 minutes.
- If the drug is prescribed as a substitute for another ophthalmic drug for the treatment of glaucoma, the latter should be discontinued and Travaxal should be started the next day.
- Order of operation of the emphasis:
1. Take the stopper and the vial out of the pack.
Open the bottle using the stopper. 3.
3. Fasten the stop to the neck of the vial.
4. Place the stopper on the eyelid so that the dropper is in front of the eyeball, drip the desired amount of drug.
5. Remove the stopper from the neck of the bottle.
Close the bottle with the cap.
